A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma. It also provides Hydrogel (Hioxifilcon A) Soft (Hydrophilic) Contact Lens, a spherical and aspherical lenses. In addition, the company supplies drugs and medical materials for clinical trials; and operates DNA methylation-based oncology testing programs. Further, it provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination, and compliance-focused support for clinical development programs to pharmaceutical and biotechnology companies. It serves corporate and retail customers. The company was founded in 2013 and is based in Taipei, Taiwan.
Financial Summary
| Share Statistics | YDES | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $397.4 | $228.4 | 36% |
|
| Shares Out (Mil) | 1.1 | 53.9 | 5% |
|
| Institutional Ownership | 0.6% | 92.9% | 2% |
|
| Float (Mil) | 16.2 | 41.7 | 26% |
|
| Beta | -0.16 | 0.95 | 4% |
|
| Avg Daily Volume (000s) | 117 | 582 | 38% |
|
| Price Change (52-week) |
(72.1%) | 47.6% | 11% |
|
| Growth | YDES | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | YDES | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $37 | 1% |
|
| Net Income (TTM) (Mil) | ($8) | ($44) | 30% |
|
| EPS (TTM) | ($0.125) | ($1.500) | 35% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | ($33) | 23% |
|
| Net Cash Flow (TTM) (Mil) | $3 | $2 | 50% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $42 | $177 | 15% |
|
| Valuation | YDES | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.23 | 2.19 | 34% |
|
| P/E | na | 19.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | YDES | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 29.6% | 66.9% | 35% |
|
| Net Margin | 24.7% | (73.7%) | 83% |
|
| ROA | (231.3%) | (47.1%) | 2% |
|
| ROE | (251.4%) | (54.1%) | 3% |
|
| Liabilities to Assets | 4.0% | 29.1% | 2% |
|
| F-Score | 3 | 2 | na |
|
YD Bio Limited did not pass any screens on 10/20/2026.
